INMB vs RJF · rev $50.0K vs rev $15.91B
INmune Bio Inc (INMB) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
INmune Bio Inc (INMB) is a biotechnology company listed on US.
RJF (RJF) common stock.
Latest reported INMB revenue for 2025-09-30 was $50.0K. Net income was -$6.5M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. INMB currently screens at market cap $33.5M.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
INMB currently screens at market cap $33.5M. RJF currently screens at market cap $0.
Not investment advice. Open the INMB and RJF stock pages for the full models.
Not investment advice.